Medipost Co Ltd
Company Profile
Business description
Medipost Co Ltd is a Korea-based stem cell biotechnology company. The company is engaged in developing products to meet unmet medical needs. The company operates its business through four distinct segments: Stem Cell Therapeutics, Cord Blood Bank, Cosmetics, and Health Supplements. The Cord Blood Bank Division is involved in collecting and storing stem cells from the newborn's umbilical cord. The Stem Cell Therapeutics division manufactures allogeneic stem cell drug products. The Health Supplements division offers vitamins and nutritional supplements. The Cosmetics division is involved in the sales and marketing of natural cosmetics.
Contact
21, Daewangpangyo-ro 644
Bundang-gu
Gyeonggi-do
Seongnam
KORT: +82 234656650
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
334
Stocks News & Analysis
stocks
SK Hynix Earnings: We raise fair value estimate on strong AI memory demand
stocks
Meta shares are down 12% since earnings. Is the stock a buy?
stocks
SpaceX earnings: We raise our fair value estimate on scaling data centres, but is the stock a buy?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 41.20 | 0.46% |
| CAC 40 | 7,970.00 | 83.04 | 1.05% |
| DAX 40 | 26,039.68 | 335.66 | 1.31% |
| Dow JONES (US) | 52,200.77 | 274.33 | -0.52% |
| FTSE 100 | 10,722.07 | 27.57 | 0.26% |
| HKSE | 22,958.65 | 136.18 | -0.59% |
| NASDAQ | 26,135.07 | 414.79 | -1.56% |
| Nikkei 225 | 64,659.47 | 705.28 | 1.10% |
| NZX 50 Index | 13,710.17 | 18.84 | 0.14% |
| S&P 500 | 7,701.70 | 42.28 | -0.55% |
| S&P/ASX 200 | 8,891.80 | 44.50 | 0.50% |
| SSE Composite Index | 3,651.43 | 30.04 | -0.82% |